Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial

Journal of Clinical Oncology

Volumn 29, Issue 19, 2011, Pages 2653-2659

  Pfeiler, Georg ^a   Königsberg, Robert ^b   Fesl, Christian ^c   Mlineritsch, Brigitte ^d   Stoeger, Herbert ^e   Singer, Christian F ^a   Pöstlberger, Sabine ^f   Steger, Guenther G ^a   Seifert, Michael ^a   Dubsky, Peter ^a   Taucher, Susanne ^g   Samonigg, Hellmut ^e   Bjelic Radisic, Vesna ^e   Greil, Richard ^d   Marth, Christian ^g   Gnant, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c Austrian Breast and Colorectal Cancer Study Group   (Austria)

^d Private Medical University Salzburg   (Austria)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f Krankenhaus der Barmherzigen Schwestern Linz   (Austria)

^g INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; GOSERELIN; PROGESTERONE RECEPTOR; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTHRALGIA; ARTHROPATHY; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE DENSITY; BONE PAIN; BREAST CANCER; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; DEPRESSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FATIGUE; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; JOINT STIFFNESS; MAJOR CLINICAL STUDY; MUSCULOSKELETAL PAIN; NAUSEA; OBESITY; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SLEEP DISORDER;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; GOSERELIN; HUMANS; MIDDLE AGED; NITRILES; PREMENOPAUSE; PROSPECTIVE STUDIES; RECURRENCE; RETROSPECTIVE STUDIES; RISK; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 79960128817     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.2585     Document Type: Conference Paper

References (32)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Dowsett M, Cuzick J, Ingle J, et al: Metaanalysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518, 2010
3. Jakesz R, Jonat W, Gnant M, et al: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462, 2005 (Pubitemid 41111693)
4. Jonat W, Gnant M, Boccardo F, et al: Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis. Lancet Oncol 7:991-996, 2006 (Pubitemid 44804137)
5. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
6. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
7. Parton M, Smith IE: Controversies in the management of patients with breast cancer: Adjuvant endocrine therapy in premenopausal women. J Clin Oncol 26:745-752, 2008 (Pubitemid 351264387)
8. Dowsett M, Stein RC, Coombes RC: Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol 43:155-159, 1992
9. Cuzick J, Ambroisine L, Davidson N, et al: Use of luteinising-hormone- releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: A meta-analysis of individual patient data from randomised adjuvant trials. Lancet 369:1711-1723, 2007
10. Francis P, Fleming G, Nasi ML, et al: Tailored treatment investigations for premenopausal women with endocrine responsive (ER- and/or PgR-) breast cancer: The SOFT, TEXT, and PERCHE trials. Breast 12:S44, 2003 (suppl; abstr P104)
11. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009
12. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
13. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442, 2003 (Pubitemid 36682823)
14. Key TJ, Appleby PN, Reeves GK, et al: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95:1218-1226, 2003 (Pubitemid 37069552)
15. Longcope C, Baker R, Johnston CC: Androgen and estrogen metabolism: Relationship to obesity. Metabolism 35:235-237, 1986
16. MacDonald PC, Edman CD, Hemsell DL, et al: Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 130:448-455, 1978 (Pubitemid 8291952)
17. Forney JP, Milewich L, Chen GT, et al: Aromatization of androstenedione to estrone by human adipose tissue in vitro: Correlation with adipose tissue mass, age, and endometrial neoplasia. J Clin Endocrinol Metab 53:192-199, 1981 (Pubitemid 13245403)
18. Rose DP, Komninou D, Stephenson GD: Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5:153-165, 2004 (Pubitemid 38998240)
19. Probst-Hensch NM, Ingles SA, Diep AT, et al: Aromatase and breast cancer susceptibility. Endocr Relat Cancer 6:165-173, 1999 (Pubitemid 29260048)
20. Carlson RW, Theriault R, Schurman CM, et al: Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor - positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol 28:3917-3921, 2010
21. Parr CL, Batty GD, Lam TH, et al: Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: Pooled analyses of 424,519 participants. Lancet Oncol 11:741-752, 2010
22. Protani M, Coory M, Martin JH: Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res Treat 123:627-635, 2010
23. de Azambuja E, McCaskill-Stevens W, Francis P, et al: The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: The experience of the BIG 02-98 trial. Breast Cancer Res Treat 119:145-153, 2010
24. Ewertz M, Jensen M-B, Gunnarsdottir K, et al: Effects of obesity on prognosis after early breast cancer. Cancer Res 69:24s, 2009 (suppl; abstr 18)
25. Powell K: Obesity: The two faces of fat. Nature 447:525-527, 2007
26. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002 (Pubitemid 34032594)
27. Gunter MJ, Hoover DR, Yu H, et al: Insulin, insulinlike growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101:48-60, 2009
28. Hamelers IH, Steenbergh PH: Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 10:331-345, 2003 (Pubitemid 36758659)
29. Kato S, Endoh H, Masuhiro Y, et al: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491-1494, 1995
30. Dignam JJ, Wieand K, Johnson KA, et al: Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95:1467-1476, 2003 (Pubitemid 37279332)
31. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002 (Pubitemid 34694019)
32. Sestak I, Distler W, Forbes JF, et al: Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol 28:3411-3415, 2010